We are live on ! Find out more
SMMT icon

Summit Therapeutics

52 hedge funds and large institutions have $11.7M invested in Summit Therapeutics in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.14% less ownership

Funds ownership: 11.37%11.23% (-0.14%)

5% less funds holding

Funds holding: 5552 (-3)

14% less capital invested

Capital invested by funds: $13.6M → $11.7M (-$1.89M)

18% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 11

35% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 17

Holders
52
Holders Change
-3
Holders Change %
-5.45%
% of All Funds
0.82%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
11
Reduced
17
Closed
11
Calls
$33K
Puts
Net Calls
+$33K
Net Calls Change
-$51K
Name Holding Trade Value Shares
Change
Change in
Stake
VW
26
Vance Wealth
California
$33K +$2.52K +1,000 +8%
AIG
27
American International Group
New York
$32K -$2.32K -920 -7%
CAPTRUST Financial Advisors
28
CAPTRUST Financial Advisors
North Carolina
$28K
Invesco
29
Invesco
Georgia
$28K +$1.47K +584 +5%
California State Teachers Retirement System (CalSTRS)
30
California State Teachers Retirement System (CalSTRS)
California
$27K -$6.26K -2,485 -18%
VOYA Investment Management
31
VOYA Investment Management
Georgia
$26K
Bank of America
32
Bank of America
North Carolina
$24K -$24K -9,517 -49%
Osaic Holdings
33
Osaic Holdings
Arizona
$24K -$378 -150 -2%
PCH
34
Polar Capital Holdings
United Kingdom
$15.4K +$390K +154,598 +3%
AB
35
Amalgamated Bank
New York
$11K +$10.8K +4,291 New
AF
36
Amalgamated Financial
New York
$11K +$10.8K +4,291 New
Barclays
37
Barclays
United Kingdom
$11K +$11K +4,361 New
TRCT
38
Tower Research Capital (TRC)
New York
$10K +$239 +95 +2%
Citigroup
39
Citigroup
New York
$8K -$18.2K -7,212 -69%
National Bank of Canada
40
National Bank of Canada
Quebec, Canada
$8K
Legal & General Group
41
Legal & General Group
United Kingdom
$7K
ATC
42
Adirondack Trust Company
New York
$6K +$3.78K +1,500 +150%
TCWA
43
Ten Capital Wealth Advisors
Washington
$5K +$5.04K +2,000 New
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$4K -$10.7K -4,226 -72%
AIP
45
Ameritas Investment Partners
Nebraska
$4K
Fidelity Investments
46
Fidelity Investments
Massachusetts
$2K +$1.84K +729 New
Daiwa Securities Group
47
Daiwa Securities Group
Japan
$1K
WAM
48
Worth Asset Management
Texas
$1K +$2.52K +1,000 New
AGM
49
Alpine Global Management
New York
$380
Russell Investments Group
50
Russell Investments Group
United Kingdom
-$582K -216,991 Closed

SMMT Hedge Fund Activity: Q1 2022 in Review

52 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2022, worth a combined $11.7M — down 14% from $13.6M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of SMMT and 9 opened new positions — a net loss of 2 holders — while 17 trimmed existing stakes and 11 added.

The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $391K. The largest seller was Russell Investments Group, exiting entirely with an estimated $582K sold.

  • 52 institutional investors held Summit Therapeutics (SMMT) as of Q1 2022, down from 55 in Q4 2021.
  • Funds reported $11.7M of Summit Therapeutics stock for Q1 2022, down 14% quarter-over-quarter.
  • 9 funds opened new Summit Therapeutics positions in Q1 2022 and 11 closed out, a net change of -2 holders.
  • The largest Summit Therapeutics buyer in Q1 2022 was Boothbay Fund Management, an estimated $391K added.
  • The largest Summit Therapeutics seller in Q1 2022 was Russell Investments Group, an estimated $582K sold.

Based on aggregated 13F filings for Q1 2022.